Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147973 | 0.95 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1PTGS1PTGS2MEN1 | |
| SCHEMBL1147959 | 0.90 | HSP90AA1 (0.35) | HSP90AA1HSP90AB1PTGS1PTGS2MEN1 | |
| SCHEMBL1148633 | 0.90 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1 | |
| SCHEMBL14618214 | 0.86 | HSP90AA1 (0.38) | HSP90AA1HSP90AB1 | |
| SCHEMBL1148791 | 0.86 | HSP90AA1 (0.35) | HSP90AA1HSP90AB1PTGS1PTGS2MEN1 | |
| SCHEMBL1148714 | 0.85 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1PTGS1PTGS2CRHR1 | |
| SCHEMBL1147967 | 0.85 | LMNA (0.34) | HSP90AA1HSP90AB1CRHR1MEN1KMT2A | |
| SCHEMBL1148578 | 0.84 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1PTGS1PTGS2MEN1 | |
| SCHEMBL13108657 | 0.83 | CRHR1 (0.34) | HSP90AA1HSP90AB1CRHR1MEN1GAA | |
| SCHEMBL1148760 | 0.81 | CYP3A4 (0.35) | HSP90AA1HSP90AB1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144398-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2019-05-16 | — | — | US | disclosed |
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2017-11-09 | — | — | US | disclosed |
| US-20160000756-A1 | IMIDAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160000756-A1 | IMIDAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-07 | — | — | US | disclosed |
| US-9156794-B2 | Imidazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156794-B2 | Imidazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | SYNTA PHARMACEUTICALS CORP. | 2010-09-30 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20070087998-A1 | Imidazole compounds that modulate HSP90 activity | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2007-04-19 | — | — | US | disclosed |
| US-20070087998-A1 | Imidazole compounds that modulate HSP90 activity | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2007-04-19 | — | — | US | disclosed |
| WO-2007021877-A1 | IMIDAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AA1 4/4885HSP90AB1 1/4885PTGS1 607/4885 |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | TOP2A, TOP2B, TOP1 | HSP90AA1 8/4885HSP90AB1 6/4885PTGS1 536/4885 |
| US-20160000756-A1 | IMIDAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885PTGS1 448/4885 |
| US-20190144398-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | HSP90AA1 531/4885HSP90AB1 605/4885PTGS1 31/4885 |
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | HSP90AA1 531/4885HSP90AB1 605/4885PTGS1 31/4885 |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885PTGS1 2644/4885 |
| US-20070087998-A1 | Imidazole compounds that modulate HSP90 activity | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885PTGS1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.